We Need to Talk About CRISPR
By Staff,
The Medicine Maker
| 03. 21. 2025
"The Promise and Peril of CRISPR" cover by Johns Hopkins University Press
As a paediatrician taking care of children with sickle cell disease, Neal Baer, a Harvard Medical School graduate, was in awe of the power of CRISPR technologies. Later becoming a TV show writer (for hit shows such as ER, Law and Order, and Under the Dome), Baer realized that the promise of advanced medicine could quickly become a peril, if placed in the wrong hands. This inspired him to compile a collection of essays that asks how far could – or should – humanity develop it. The Promise and the Peril of CRISPR chronicles the human condition in the 21st century, and asks what is more valuable: saving lives, or wielding power? Here he discusses the duality of CRISPR.
What inspired you to compile a collection of essays about CRISPR specifically?
There are lots of reasons. It’s important to know who has access to the data, and the DNA. Is it safe? What are the unforeseen consequences? Will there still be problems once one piece of DNA...
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...